Covid19

An antibody isolated from people in India who recovered from COVID-19 can broadly neutralise SARS-CoV-2 variants, including Omicron sub-lineages.

The “COVID-19: Community access diagnostics laboratory networks” project implemented by ICGEB, in partnership with New England Biolabs^® (NEB^®), and funded by the Bill & Melinda Gates Foundation, kicked-off with a virtual meeting on 16 February 2022.

The ICGEB symposium on COVID19 highlights ICGEB activities related to COVID-19 and feedback on how to cooperate against future challenges – playlist now available

ICGEB Trieste and Nicolae Testemitanu State University have organised a 3-day workshop to strengthen the surveillance capacity to address COVID-19 and other epidemics in Moldova. The workshop will take place online from Tuesday 21 to Thursday 23 September 2021.

A pilot study on cost-effective SARS-CoV-2 testing, coordinated by ICGEB, has been successfully extended to the second phase in 9 countries in Africa.

“COVID-19: Establishing rapid laboratory diagnostics programs in LMICs” is a project coordinated by the ICGEB and implemented in partnership with reference testing laboratories in Africa. We are pleased to present the video of the project.

Amongst its activities with the United Nations, ICGEB links with 2030 CONNECT – a UN online technology platform for the SDGs.

7 April 2021: Published today in Nature, Researchers in London and Trieste discover the mechanism that leads to the fusion of cells infected with Sars-Cov-2 and a drug capable of blocking this process.

On the occasion of World Health Day, 7 April 2021, we meet the scientists in ICGEB Member States who have received CRP Grants for their research into COVID-19.

17 March 2021: One year into Covid-19, ICGEB Principal Investigators from Trieste, New Delhi, and Cape Town present their research and work in the field at the ICGEB Symposium.